AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
AZN•AstraZeneca filed a US FDA application seeking approval of the ORPATHYS-TAGRISSO combination for patients with advanced lung cancer, HUTCHMED said.
1. FDA application
HUTCHMED said AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
